2009
IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas
Hoyo C, Schildkraut JM, Murphy SK, Chow W, Vaughan TL, Risch H, Marks JR, Jirtle RL, Calingeart B, Mayne S, Fraumeni J, Gammon MD. IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas. International Journal Of Cancer 2009, 125: 2673-2678. PMID: 19626700, PMCID: PMC3008656, DOI: 10.1002/ijc.24623.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsRisk of esophagealInsulin-like growth factor 2Gastric adenocarcinomaGastric cancerEsophageal squamous cell carcinomaNoncardia gastric adenocarcinomaNoncardia gastric cancerSquamous cell carcinomaExploratory subgroup analysisAnti-inflammatory drugsMannose-6-phosphate/insulin-like growth factor 2 receptorNoncardia adenocarcinomaGrowth factor 2Cigarette smokersCell carcinomaSubgroup analysisGrowth factor 2 receptorInsulin-like growth factor 2 receptorCardia adenocarcinomaFactor 2 receptorG alleleNonsynonymous genetic variantsAdenocarcinomaStudy participantsPolymorphic Variation of Genes in the Fibrinolytic System and the Risk of Ovarian Cancer
Bentov Y, Brown TJ, Akbari MR, Royer R, Risch H, Rosen B, McLaughlin J, Sun P, Zhang S, Narod SA, Casper RF. Polymorphic Variation of Genes in the Fibrinolytic System and the Risk of Ovarian Cancer. PLOS ONE 2009, 4: e5918. PMID: 19526059, PMCID: PMC2691597, DOI: 10.1371/journal.pone.0005918.Peer-Reviewed Original ResearchConceptsOvarian cancerSingle nucleotide polymorphismsCandidate genesFibrinolytic systemGenesFunctional variantsFunctional SNPsNucleotide polymorphismsPolymorphic variationBlood clot degradationOvarian cancer casesFunctional effectsSNPsHistologic subgroupsRetrograde menstruationCancer casesClot degradationGenotype distributionBlood clotsSignificant associationCancerFibrin productsGermlineInefficient removalRisk
2007
Alcohol dehydrogenase 3 and risk of esophageal and gastric adenocarcinomas
Terry MB, Gammon MD, Zhang FF, Vaughan TL, Chow WH, Risch HA, Schoenberg JB, Mayne ST, Stanford JL, West AB, Rotterdam H, Blot WJ, Fraumeni JF, Santella RM. Alcohol dehydrogenase 3 and risk of esophageal and gastric adenocarcinomas. Cancer Causes & Control 2007, 18: 1039-1046. PMID: 17665311, DOI: 10.1007/s10552-007-9046-0.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAlcohol DehydrogenaseAlcohol DrinkingAllelesCase-Control StudiesChi-Square DistributionConfidence IntervalsEsophageal NeoplasmsFemaleGene FrequencyGenotypeHomozygoteHumansInterviews as TopicLogistic ModelsMaleMiddle AgedOdds RatioPolymorphism, GeneticRisk FactorsStomach NeoplasmsUnited StatesConceptsRisk of esophagealEsophageal adenocarcinomaHigh riskGastric Cancer StudyGastric cardia adenocarcinomaGastric adenocarcinomaCarcinoma riskConclusionThese dataCancer riskCardia adenocarcinomaTumor typesAdenocarcinomaAlcohol dehydrogenase 3Common polymorphismsEsophagealRisk estimatesCancer studiesRiskAlcohol dehydrogenase 3 geneDrinkersDehydrogenase 3PolymorphismNondrinkersMethodsWeGenotypesIGF-I in epithelial ovarian cancer and its role in disease progression
Brokaw J, Katsaros D, Wiley A, Lu L, Su D, Sochirca O, de la Longrais IA, Mayne S, Risch H, Yu H. IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors 2007, 25: 346-354. PMID: 18236213, DOI: 10.1080/08977190701838402.Peer-Reviewed Original ResearchConceptsIGF-I transcriptsDisease progressionOvarian cancerTumor progressionEpithelial ovarian cancer patientsIGF-I mRNA expressionInsulin-like growth factorParacrine/autocrine regulationIGF-I activityEpithelial ovarian cancerIGF-I actionOvarian cancer patientsFresh tumor samplesIGF-I expressionIGF-I mRNAOvarian cancer progressionEnzyme-linked immunosorbentParacrine/autocrineTotal IGFFree IGFClinicopathologic featuresCA polymorphismCancer patientsReal-time PCRElevated riskGST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas
Wideroff L, Vaughan TL, Farin FM, Gammon MD, Risch H, Stanford JL, Chow WH. GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas. Cancer Epidemiology 2007, 31: 233-236. PMID: 17646057, PMCID: PMC2268246, DOI: 10.1016/j.cdp.2007.03.004.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAllelesArylamine N-AcetyltransferaseCase-Control StudiesCytochrome P-450 CYP1A1Esophageal NeoplasmsFemaleGenetic Predisposition to DiseaseGlutathione S-Transferase piGlutathione TransferaseHumansIsoenzymesMaleMiddle AgedOdds RatioPolymerase Chain ReactionPolymorphism, GeneticRisk FactorsStomach NeoplasmsUnited StatesConceptsGastric adenocarcinomaOdds ratioGastric cardia adenocarcinomaEsophageal adenocarcinomaCardia adenocarcinomaElevated riskConfidence intervalsVal genotypePopulation-based case-control studyCYP1A1 Val/ValGSTP1 Val/Val genotypeNoncardia gastric adenocarcinomaEpidemiologic risk factorsRespective odds ratiosRisk of esophagealIle/Val genotypeVal/Val genotypeCase-control studyVal/ValN-acetyltransferase 1Same catchment areaHistologic subgroupsIncident casesRisk factorsGSTT1 genotype
2006
A Functional Polymorphism of Toll-Like Receptor 4 Gene Increases Risk of Gastric Carcinoma and Its Precursors
Hold GL, Rabkin CS, Chow W, Smith MG, Gammon MD, Risch HA, Vaughan TL, McColl KE, Lissowska J, Zatonski W, Schoenberg JB, Blot WJ, Mowat NA, Fraumeni JF, El–Omar E. A Functional Polymorphism of Toll-Like Receptor 4 Gene Increases Risk of Gastric Carcinoma and Its Precursors. Gastroenterology 2006, 132: 905-912. PMID: 17324405, DOI: 10.1053/j.gastro.2006.12.026.Peer-Reviewed Original ResearchMeSH KeywordsAchlorhydriaCarcinomaCase-Control StudiesCohort StudiesEuropeFemaleGastritis, AtrophicGene Expression Regulation, NeoplasticGene FrequencyGenetic Predisposition to DiseaseGenotypeHelicobacter InfectionsHelicobacter pyloriHumansLogistic ModelsMaleOdds RatioPhenotypePolymorphism, GeneticPopulation SurveillancePrecancerous ConditionsRegistriesRisk AssessmentRisk FactorsStomach NeoplasmsToll-Like Receptor 4United StatesConceptsH pylori infectionGastric carcinoma patientsNoncardia gastric carcinomaOdds ratioGastric carcinomaCardia carcinomaGastric atrophyCarcinoma patientsPylori infectionG polymorphismPopulation-based case-control studyUpper gastrointestinal tract cancerSevere gastric atrophyFrequency-matched controlsGastric acid outputGastrointestinal tract cancerGastric cancer patientsGastric cardia carcinomaCase-control studyEsophageal squamous cellsPotential confounding factorsGastric carcinoma casesGastric changesTract cancerAcid outputPGR +331 A/G and Increased Risk of Epithelial Ovarian Cancer
Risch HA, Bale AE, Beck PA, Zheng W. PGR +331 A/G and Increased Risk of Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers & Prevention 2006, 15: 1738-1741. PMID: 16985038, DOI: 10.1158/1055-9965.epi-06-0272.Peer-Reviewed Original ResearchConceptsOvarian cancerA allelePostmenopausal womenProgesterone receptor gene polymorphismHistologic tumor typePopulation-based studyEpithelial ovarian cancerEffect of progesteroneReceptor gene polymorphismsPremenopausal womenEndometrial cancerMenopausal statusOral contraceptivesOvarian neoplasiaProgesterone receptorProgestin exposureG genotypeGG genotypeGene polymorphismsTumor typesReceptor isoformsCancerWomenRiskProgesterone
2005
Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival
Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M, Risch H, Jones B, Yu H. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecologic Oncology 2005, 100: 330-337. PMID: 16199080, DOI: 10.1016/j.ygyno.2005.08.035.Peer-Reviewed Original ResearchConceptsOvarian cancer treatmentDisease progressionGSTP1 genotypesGST polymorphismsPrimary epithelial ovarian cancerCox proportional hazards regressionFunctional polymorphismsGSTP1 Ile/IleCancer treatmentGSTP1 Ile/ValGlutathione S-transferase polymorphismsGSTM1 null patientsPost-operative chemotherapySubgroup of patientsProportional hazards regressionEpithelial ovarian cancerOvarian cancer survivalEffect of chemotherapyOvarian cancer prognosisOvarian cancer progressionVal/ValIle/IleIle/ValOverall survivalTumor characteristics
2003
The N314D polymorphism of galactose-1-phosphate uridyl transferase does not modify the risk of ovarian cancer.
Fung WL, Risch H, McLaughlin J, Rosen B, Cole D, Vesprini D, Narod SA. The N314D polymorphism of galactose-1-phosphate uridyl transferase does not modify the risk of ovarian cancer. Cancer Epidemiology Biomarkers & Prevention 2003, 12: 678-80. PMID: 12869412.Peer-Reviewed Original ResearchIncreased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms
El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, Stanford JL, Mayne ST, Goedert J, Blot WJ, Fraumeni JF, Chow WH. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003, 124: 1193-1201. PMID: 12730860, DOI: 10.1016/s0016-5085(03)00157-4.Peer-Reviewed Original ResearchConceptsProinflammatory cytokine gene polymorphismsNoncardia gastric cancerUpper gastrointestinal cancerCytokine gene polymorphismsGastric cancerIL-10Gastrointestinal cancerReceptor antagonistGene polymorphismsPopulation-based case-control studyCytokine genesTumor necrosis factor AAnti-inflammatory cytokine genesIL-1 receptor antagonistGastric H. pylori infectionEsophageal squamous cell carcinomaHelicobacter pylori-related gastric cancerTumor necrosis factor alphaNoncardia gastric adenocarcinomaIL-1 gene clusterFrequency-matched controlsSquamous cell carcinomaH. pylori infectionGastric cardia cancerCase-control study